161 related articles for article (PubMed ID: 37097008)
1. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef N; Castillo C; Mosteiro M; Pérez X; Aguilar S; Ruíz-Pace F; Gil M; Cuadra C; Ruffinelli JC; Martínez M; Losa F; Soler G; Teulé À; Castany R; Gallego R; Ruíz A; Garralda E; Élez E; Vivancos A; Tabernero J; Salazar R; Dienstmann R; Santos Vivas C
Mol Oncol; 2023 Sep; 17(9):1908-1916. PubMed ID: 37097008
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
[TBL] [Abstract][Full Text] [Related]
3. Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population.
Nindra U; Pal A; Lea V; Lim SH; Wilkinson K; Asghari R; Roberts TL; Becker TM; Farzin M; Rutland T; Lee M; MacKenzie S; Ng W; Wang B; Lee CS; Chua W
PLoS One; 2023; 18(10):e0292087. PubMed ID: 37796807
[TBL] [Abstract][Full Text] [Related]
4. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Condorelli R; Mosele F; Verret B; Bachelot T; Bedard PL; Cortes J; Hyman DM; Juric D; Krop I; Bieche I; Saura C; Sotiriou C; Cardoso F; Loibl S; Andre F; Turner NC
Ann Oncol; 2019 Mar; 30(3):365-373. PubMed ID: 30715161
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
Hsieh LL; Er TK; Chen CC; Hsieh JS; Chang JG; Liu TC
Clin Chim Acta; 2012 Oct; 413(19-20):1605-11. PubMed ID: 22579930
[TBL] [Abstract][Full Text] [Related]
6. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
[TBL] [Abstract][Full Text] [Related]
7. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
[TBL] [Abstract][Full Text] [Related]
8. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
[TBL] [Abstract][Full Text] [Related]
9. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
Hirshfield KM; Tolkunov D; Zhong H; Ali SM; Stein MN; Murphy S; Vig H; Vazquez A; Glod J; Moss RA; Belyi V; Chan CS; Chen S; Goodell L; Foran D; Yelensky R; Palma NA; Sun JX; Miller VA; Stephens PJ; Ross JS; Kaufman H; Poplin E; Mehnert J; Tan AR; Bertino JR; Aisner J; DiPaola RS; Rodriguez-Rodriguez L; Ganesan S
Oncologist; 2016 Nov; 21(11):1315-1325. PubMed ID: 27566247
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
11. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
Matsumoto A; Shimada Y; Nakano M; Oyanagi H; Tajima Y; Nakano M; Kameyama H; Hirose Y; Ichikawa H; Nagahashi M; Nogami H; Maruyama S; Takii Y; Ling Y; Okuda S; Wakai T
Oncol Rep; 2020 Jun; 43(6):1853-1862. PubMed ID: 32236609
[TBL] [Abstract][Full Text] [Related]
12. Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients.
Melisi D; Cavaliere A; Gobbo S; Fasoli G; Allegrini V; Simionato F; Gaule M; Casalino S; Pesoni C; Zecchetto C; Merz V; Mambrini A; Barbi E; Girelli R; Giardino A; Frigerio I; Scalamogna R; Avitabile A; Castellani S; Milella M; Butturini G
Pancreatology; 2021 Apr; ():. PubMed ID: 33896692
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.
Shimada Y; Tajima Y; Nagahashi M; Ichikawa H; Oyanagi H; Okuda S; Takabe K; Wakai T
J Surg Res; 2018 Dec; 232():72-81. PubMed ID: 30463788
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer-A Nation-Wide Study.
Potocki PM; Wójcik P; Chmura Ł; Goc B; Fedewicz M; Bielańska Z; Swadźba J; Konopka K; Kwinta Ł; Wysocki PJ
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240418
[TBL] [Abstract][Full Text] [Related]
16. Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
Poulsen TS; de Oliveira DVNP; Espersen MLM; Klarskov LL; Skovrider-Ruminski W; Hogdall E
APMIS; 2021 Feb; 129(2):61-69. PubMed ID: 33075161
[TBL] [Abstract][Full Text] [Related]
17. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
[No Abstract] [Full Text] [Related]
18. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
20. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
